US FDA warns against PharmaTech LLC-made meds over B.cepacia risk

By Gareth Macdonald

- Last updated on GMT

iStock/10174593_258
iStock/10174593_258

Related tags Pharmaceutical drug Fda

The US FDA has warned doctors not to use any liquid drugs made by PharmaTech LLC over renewed concerns they may be contaminated with the bacteria Burkholderia cepacia.

The US regulator issued the warning on Tuesday, citing Michigan–based Rugby Laboratories’ withdrawal of two products - Diocto Liquid and Diocto Syrup – that had been made on its behalf by PharmaTech.

It said “Centers for Disease Control and Prevention laboratory testing of PharmaTech’s oral liquid docusate detected a strain of B. cepacia, bacteria linked to recent patient infections. Therefore, FDA recommends health care professionals and patients not use PharmaTech’s liquid drug products​.”

In addition, the agency warned companies that have bought products from the Florida, US-based contractor to “immediately quarantine” the medicines.

Recalls

Burkholdia cepacia​ has been a concern in the US for several years.

Last year​ the US Centres for Disease Control (CDC) reported a surge in infections in several States.

The FDA later​ linked the outbreak to contaminated constipation remedies made by PharmaTech LLC​.

PharmaTech recalled​ products made at its facility in Davie, Florida last summer.

The FDA also investigated Laxachem Organics Pvt. Ltd, an Indian active pharmaceutical ingredient supplier​ (API) that makes docusate sodium USP, the ingredient in the recalled products.

However, the agency later concluded​ Laxachem had not supplied PharmaTech and was not the source of the bacterial contamination.

In October​, a separate outbreak of Burkholderia cepacia infections was linked to contaminated prefilled saline flush syringes manufactured by Nurse Assist at its facility in Haltom City, Texas.

The syringes were recalled​ later that month.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars